Invasive Meningococcal Disease
Conditions
Brief summary
Active metropolitan area surveillance for hospital admissions related to invasive infection with Neisseria meningitidis will be conducted at the 12 centers in the IMPACT network in collaboration with Public Health officials, local infection specialists and infection control practitioners during the interval from January 1, 2016 to December 31, 2022.
Detailed description
The objectives are 3-fold, including: 1. description of affected children and adults and the nature and outcome of the infection episodes 2. incidence rate determination in defined populations, by age, serogroup and study year 3. detailed study of the organisms recovered from cases
Interventions
OTHERsurveillance
Sponsors
Pfizer
GlaxoSmithKline
Canadian Paediatric Society
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
1 Minutes to No maximum
Healthy volunteers
No
Inclusion criteria
Neisseria meningitidis isolated or detected by PCR from a normally sterile body site or fluid, such as blood, CSF, joint fluid, pleural, peritoneal, pericardial fluid or tissue biopsy -
Exclusion criteria
patients diagnosed based only on 1. clinical signs, gram stain, or antigen test 2. meningococci isolated only from respiratory tract, including conjunctiva, sinuses, middle ear/mastoid, throat, peritonsillar abscess, cervical lymph node, tracheal aspirate, bronchial lavage etc -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Laboratory confirmed invasive meningococcal cases. | End of 2021 | Laboratory confirmed invasive meningococcal cases. |
Countries
Canada
Contacts
Primary ContactMelanie Laffin Thibodeau
Backup ContactMarie Adele Davis
Outcome results
None listed